Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 2
2007 3
2008 2
2009 3
2010 4
2011 3
2013 3
2014 2
2015 1
2016 1
2017 8
2018 6
2019 4
2020 1
2021 2
2022 6
2023 19
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.
Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, Hardin M. Wechsler ME, et al. Among authors: domingo c. Lancet Respir Med. 2022 Jan;10(1):11-25. doi: 10.1016/S2213-2600(21)00322-2. Epub 2021 Sep 28. Lancet Respir Med. 2022. PMID: 34597534 Clinical Trial.
Tezepelumab in patients with allergic and eosinophilic asthma.
Caminati M, Buhl R, Corren J, Hanania NA, Kim H, Korn S, Lommatzsch M, Martin N, Matucci A, Nasser SM, Pavord ID, Domingo C. Caminati M, et al. Among authors: domingo c. Allergy. 2023 Dec 26. doi: 10.1111/all.15986. Online ahead of print. Allergy. 2023. PMID: 38146651 Review.
Chronic Cough.
Pacheco A, de Diego A, Domingo C, Lamas A, Gutierrez R, Naberan K, Garrigues V, López Vime R. Pacheco A, et al. Among authors: domingo c. Arch Bronconeumol. 2015 Nov;51(11):579-89. doi: 10.1016/j.arbres.2015.03.019. Epub 2015 Jul 10. Arch Bronconeumol. 2015. PMID: 26165783 English, Spanish.
Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma.
Jackson DJ, Bacharier LB, Phipatanakul W, Sher L, Domingo C, Papadopoulos N, Modena B, Li N, Xia C, Kamal MA, Dillon M, Wolfe K, Gall R, Amin N, Mannent LP, Laws E, Rowe PJ, Jacob-Nara JA, Deniz Y, Lederer DJ, Hardin M, Xu C. Jackson DJ, et al. Among authors: domingo c. Ann Allergy Asthma Immunol. 2023 Jul;131(1):44-51.e4. doi: 10.1016/j.anai.2023.03.014. Epub 2023 Mar 22. Ann Allergy Asthma Immunol. 2023. PMID: 36958470 Free article. Clinical Trial.
The Incredible Adventure of Omalizumab.
Domingo C, Monserrate DR, Sogo A, Mirapeix RM. Domingo C, et al. Int J Mol Sci. 2024 Mar 6;25(5):3056. doi: 10.3390/ijms25053056. Int J Mol Sci. 2024. PMID: 38474304 Free PMC article. Review.
Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.
Papadopoulos NG, Szefler SJ, Bacharier LB, Maspero JF, Domingo C, Fiocchi A, Lee JK, Daizadeh N, Lederer DJ, Hardin M, Gall R, Djandji M, Siddiqui S, Jacob-Nara JA, Deniz Y, Rowe PJ. Papadopoulos NG, et al. Among authors: domingo c. Allergy. 2023 Aug;78(8):2157-2167. doi: 10.1111/all.15743. Epub 2023 May 25. Allergy. 2023. PMID: 37059696
63 results